Taegyun Park

Taegyun Park

Auto-generated profile, based on publicly available information

Taegyun Park

Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2021 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
JBJaehyun Bae
Jaehyun Bae
TPTaegyun Park
Taegyun Park
HKHyeyoung Kim
Hyeyoung Kim
MLMinyoung Lee
Minyoung Lee
BCBong-Soo Cha
Bong-Soo Cha
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor γ. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to pioglitazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.

18 March 2025 in Circulation
Verified
Journal Article
Closed access
DKDanbee Kang
Danbee Kang
GCGwang-Jun Choi
Gwang-Jun Choi
JHJihye Heo
Jihye Heo
SPSeung Woo Park
Seung Woo Park
JSJuyoung Sung
Juyoung Sung
JHJune Huh
June Huh

31 July 2022 in Cardiovascular Prevention and Pharmacotherapy
Verified
Journal Article
Open access
TPTaegyun Park
Taegyun Park
KHKyungdo Han
Kyungdo Han
DSDongwook Shin
Dongwook Shin
JPJong-Ho Park
Jong-Ho Park
Background: Dyslipidemia is common in patients with type 2 diabetes mellitus (T2D) and contributes to an increased risk of cardiovascular disease. Previous studies have shown that treatment with thiazolidinediones (TZDs) and sodium-glucose cotransporter-2 inhibitors (SGLT2-i) may help to improve dyslipidemia in T2D patients. In this study, we investigated whether patients treated with TZD and SGLT2-i showed greater improvement in high-density lipoprotein cholesterol (HDL-C) levels than those treated with only SGLT2-i.Methods: From the National Health Insurance Service database of Korea, we extracted all patients who first received SGTL2-i from 2014 to 2016. Propensity score matching was performed to balance the two groups: group A (SGTL2-i and TZD, regardless of other antidiabetic medications) and group B (SGTL2-i only without TZD, regardless of other antidiabetic medications). Posttreatment HDL-C levels were compared by the Student t-test.Results: In total, 1,400 T2D patients (700 in each group) were matched by propensity score matching. There was a significant posttreatment increase in HDL-C in group A (49.54±20.03 to 51.6±12.92 mg/dL, P=0.007), but not in group B (49.14±13.52 to 49.1±2.15 mg/dL, P=0.937). Group A also showed significantly higher posttreatment HDL-C levels than group B (51.4±12.92 vs. 49.1±12.15 mg/dL, P<0.001). Regarding the secondary endpoints, posttreatment triglyceride levels were lower (P<0.001), but total cholesterol (P=0.131) and low-density lipoprotein cholesterol levels (P=0.054) were not different after treatment.Conclusions: The combination of SGTL2-i and TZD may be more effective in ameliorating dyslipidemia in T2D patients than SGLT2-i alone. However, further studies are needed to confirm this finding.

2 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DGDong Hyun Gim
Dong Hyun Gim
YHYeonkyeong Han
Yeonkyeong Han
TPTaegyun Park
Taegyun Park
TPTaek Kyu Park
Taek Kyu Park
JLJoo Myung Lee
Joo Myung Lee
KCKi Hong Choi
Ki Hong Choi
Background: Smoking cessation after a diagnosis of type 2 diabetes mellitus (T2DM) lowers cardiovascular risk, but sustained abstinence is difficult and e-cigarettes are promoted as an alternative. Whether switching to e-cigarettes confers comparable benefit is unknown.Methods: This nationwide cohort study used the Korean National Health Insurance Service database. Adults aged 40–74 years newly diagnosed with T2DM between Jan 1, 2018, and Dec 31, 2023, who smoked at the examination preceding diagnosis were included. Self-reported behaviour at the first examination after diagnosis (the index date) defined three groups: quitters, e-cigarette users, and continued combustible cigarette users. The primary outcome was myocardial infarction. Hazard ratios were estimated with Cox proportional hazards models weighted by stabilised inverse probability of treatment weights (IPTW). This study is registered with ClinicalTrials.gov, NCT07414355.Findings: Of 164,859 participants, 31,539 were quitters, 36,801 were e-cigarette users, and 96,519 continued smoking. Over a median 2·1 years (IQR:1·1–3·4), myocardial infarction occurred at 0·8, 1·4, and 1·7 events per 1000 person-years, respectively. Compared with quitters, risk was higher in e-cigarette users (IPTW-adjusted HR:1·78, 95%CI:1·21–2·62) and in continued smokers (HR:2·17, 95%CI:1·66–2·83); risk in e-cigarette users did not differ from that in continued smokers (HR:0·82, 95%CI:0·61–1·12). The pattern was similar for coronary revascularisation (HR:1·26, 95%CI:1·00–1·60 for e-cigarette users and HR:1·23, 95%CI:1·07–1·42 for continued smokers, respectively). Continued smokers also had higher risks of ischaemic stroke (HR:1·20, 95%CI:1·03–1·39) and all-cause death (HR:1·49, 95%CI:1·28–1·73), whereas estimates for e-cigarette users were 0·98 (95%CI:0·72–1·33) and 1·04 (95%CI:0·77–1·42). Dual users, who comprised 24,987 (67·9%) of e-cigarette users, had a higher myocardial infarction risk than complete switchers (HR:2·03, 95%CI:1·17–3·53).Interpretation: Among adults with newly diagnosed T2DM who smoked, cessation was associated with the lowest risk of coronary events, and switching to e-cigarettes did not reproduce this benefit. Risks of stroke and death in e-cigarette users did not differ from those in quitters, but follow-up was short. E-cigarettes should not be regarded as equivalent to cessation after a diagnosis of T2DM.

2 June 2026 in International Journal for Global Academic & Scientific Research
Verified
Journal Article
Open access
TPTea Gyun Park
Tea Gyun Park
HLHeang Jun Lim
Heang Jun Lim
JJJung Jin
Jung Jin
Dyslipidemia is a typical metabolic consequence of type 2 diabetes that increases cardiovascular disease risk considerably. Assessing the effectiveness of combination treatments is needed to improve lipid management and metabolic control. The current study demonstrates an intelligent diagnostic model called Multi-Region Quantum Hypergraph Network with Animated Oat Optimization Algorithm (MRQHN-AOOA) to look into if SGLT2 inhibitor and thiazolidinedione combo therapy can help those with diabetes type 2 with dyslipidemia. Database data from the National Health Insurance Service (NHIS) were employed for model construction. Firstly, the data were Quality-Aware Fuzzy Min-Max Neural Networks (QAFM2NN) pre-processing to eliminate missing or repeated records and normalize clinical parameters. Age, triglycerides, body mass index (BMI), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), hemoglobin A1c (HbA1c), and drug type (SGLT2i, TZD, or both) are extracted by the X-TN. They proposed MRQHN, which consists of the Multi-Region Hypergraph Self-Attention Network (MHSAN) and the Reflection Equivariant Quantum Neural Network (REQNN), to classify patients as having improved or not improved dyslipidemia. To assist with optimization and convergence, to optimize network weights, the Animated Oat Optimization Algorithm (AOOA) was put into practice. The experimental evaluation yielded excellent results, including 99.8% specificity, 99.8% F1-score, 99.7% precision, and 99.9% accuracy and sensitivity of 99.6%. Such findings confirm that MRQHN-AOOA is a reliable and accurate calculation framework to evaluate the SGLT2 inhibitor and thiazolidinedione combination therapy and make significant contributions to precision-based diabetes management.